Literature DB >> 23414443

Natural history of hepatitis C in thalassemia major: a long-term prospective study.

Maria E Lai1, Raffaella Origa, Fabrice Danjou, Gian B Leoni, Stefania Vacquer, Franco Anni, Claudia Corrias, Patrizia Farci, Giovanna Congiu, Renzo Galanello.   

Abstract

BACKGROUND: Transfusion-acquired hepatitis C virus (HCV) remains an important problem among patients with thalassemia. In this study, we evaluated the natural history of post-transfusional hepatitis C in thalassemia major, paying special attention to spontaneous viral clearance, to factors influencing the chronicity rate and fibrosis progression. DESIGN AND METHODS: A prospective study to evaluate the incidence and etiology of transfusion-related hepatitis was started in 1980. In patients who developed hepatitis C, HCV RNA, ALT, and ferritin were measured over time. The correlation between interleukin-28B gene polymorphisms and viral clearance was also analyzed.
RESULTS: Seventy-three of 135 patients (62.2%) acquired HCV. An extended follow-up (22 to 30 yr) with HCV RNA assessment was available in 52 patients. Of them, 23 (44.2%) cleared the virus. The proportion of IL-28B genotypes was different between the subjects who cleared the virus and the subjects who did not. Fibrosis progression was similar in HCV RNA-positive and HCV RNA-negative patients. Liver iron was the only factor associated with the fibrosis.
CONCLUSIONS: In thalassemia patients with HCV infection, liver iron does not play a major role in influencing the chronicity rate, whereas it is significantly associated with the fibrosis.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23414443     DOI: 10.1111/ejh.12086

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

Review 1.  Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes.

Authors:  Salah Mohamed El Sayed; Hussam Baghdadi; Ashraf Abou-Taleb; Hany Salah Mahmoud; Reham A Maria; Nagwa S Ahmed; Manal Mohamed Helmy Nabo
Journal:  J Blood Med       Date:  2014-10-30

2.  Challenging clinical cases in HCV infection.

Authors:  Alessio Strazzulla; Giovanni Matera; Selma Valerie Mammone; Vittoria Vaccaro; Vincenzo Pisani; Chiara Costa; Francesco Manti; Patrizia Doldo; Lucio Cosco; Francesco Quintieri; Francesco Cesario; Maria Carla Liberto; Aida Giancotti; Carlo Torti; Alfredo Focà
Journal:  BMC Infect Dis       Date:  2014-09-05       Impact factor: 3.090

3.  Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?

Authors:  Kalliopi Zachou; Pinelopi Arvaniti; Nikolaos K Gatselis; Kalliopi Azariadis; Georgia Papadamou; Eirini Rigopoulou; George N Dalekos
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

4.  Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.

Authors:  Tyng-Yuan Jang; Pei-Chin Lin; Ching-I Huang; Yu-Mei Liao; Ming-Lun Yeh; Yu-Sheng Zeng; Po-Cheng Liang; Wan-Yi Hsu; Shih-Pien Tsai; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Chia-Yen Dai; Chung-Feng Huang; Shyh-Shin Chiou; Wan-Long Chuang; Ming-Lung Yu
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

5.  The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study.

Authors:  Sanaa Kamal; Sara Abdelhakam; Dalia Ghoraba; Mohamed Amer Mohsen; Ahmed Abdel Salam; Hoda Hassan; Leila Nabeigh
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-11-01       Impact factor: 2.576

6.  Molecular Characterization and Disease-Related Morbidities of β-Thalassemia Patients from the Northeastern Part of Iraq.

Authors:  Shaema Amin; Sana Jalal; Kosar Ali; Luqman Rasool; Tara Osman; Omed Ali; Abdalhamid M-Saeed
Journal:  Int J Gen Med       Date:  2020-12-09

7.  The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C.

Authors:  Bita Behnava; Heidar Sharafi; Maryam Keshvari; Ali Pouryasin; Leila Mehrnoush; Shima Salimi; Pegah Karimi Elizee; Mehran Ghazimoghaddam; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-01-23       Impact factor: 0.660

Review 8.  Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials.

Authors:  Ehsan Aminizadeh; Seyed Moayyed Alavian; Ali Akbari Sari; Nasser Ebrahimi Daryani; Bita Behnava
Journal:  Hepat Mon       Date:  2016-03-06       Impact factor: 0.660

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.